A new report says that London is the top city in Europe for the life sciences industry, and ranks third worldwide after Boston and New York in the US. That puts the city above some well-recognised ...

Adcendo has tapped into the strong investor appetite for companies developing antibody-drug conjugates for cancer with an ...

Today, 36 million people in the European Union (EU) and 30 million in the US with a rare disease face the harsh reality of a ...

Sanofi has officially opened a modular biologics manufacturing facility in Singapore that is designed to allow rapid ...

The first company to take up residence in Bayer Co.Lab Berlin – initially located on the group's pharma headquarters site in ...

A strategy for women's health in England was published in 2022 under the previous Conservative government, led at the time by ...

Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, ...

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage non ...

Metrics to use to track the 2024 VPAG have been subject to discussions, with reference made to two days where talks were held (17th July and 19th July) in the July VPAG operational review meeting ...

Dr Sam Roberts, NICE chief executive, said AstraZeneca and Daiichi Sankyo had not offered a fair price for the drug Discussions aimed at making AstraZeneca and Daiichi Sankyo's Enhertu available ...

Wales has extended a scheme to harness the power of genomics to improve cancer care and prevention via an alliance with gene-sequencing giant Illumina. NHS Wales has signed a memorandum of ...

AstraZeneca plans to invest a whopping $3.5 billion to expand its R&D and manufacturing operations in the US by 2026, as part of a drive to raise its revenues to $80 billion by the end of the decade.